Contribution of Interleukin-17A to Retinal Degenerative Diseases

Huimin Zhong; Xiaodong Sun

doi:10.3389/fimmu.2022.847937

Contribution of Interleukin-17A to Retinal Degenerative Diseases

Front Immunol. 2022 Mar 22:13:847937. doi: 10.3389/fimmu.2022.847937. eCollection 2022.

Authors

Huimin Zhong^{1

2

3

4

5}, Xiaodong Sun^{1

2

3

4

5}

Affiliations

¹ Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
² National Clinical Research Center for Eye Diseases, Shanghai, China.
³ Shanghai Key Laboratory of Ocular Fundus Diseases, Shanghai, China.
⁴ Shanghai Engineering Center for Visual Science and Photomedicine, Shanghai, China.
⁵ Shanghai Engineering Center for Precise Diagnosis and Treatment of Eye Diseases, Shanghai, China.

Abstract

Retinal degenerative diseases are a leading cause of vision loss and blindness throughout the world, characterized by chronic and progressive loss of neurons and/or myelin. One of the common features of retinal degenerative diseases and central neurodegenerative diseases is chronic neuroinflammation. Interleukin-17A (IL-17A) is the cytokine most closely related to disease in its family. Accumulating evidence suggests that IL-17A plays a key role in human retinal degenerative diseases, including age-related macular degeneration, diabetic retinopathy and glaucoma. This review aims to provide an overview of the role of IL-17A participating in the pathogenesis of retinal degenerative diseases, which may open new avenues for potential therapeutic interventions.

Keywords: age-related macular degeneration; diabetic retinopathy; glaucoma; interleukin-17A; retinal degenerative diseases.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Diabetic Retinopathy* / pathology
Humans
Interleukin-17* / physiology
Macular Degeneration*
Retina / pathology
Retinal Degeneration*

Substances

IL17A protein, human
Interleukin-17